Last reviewed · How we verify
PI3K inhibitor BKM120
At a glance
| Generic name | PI3K inhibitor BKM120 |
|---|---|
| Also known as | BKM120, PI3K_Inhibitor_BKM120, Buparlisib |
| Sponsor | Kami Maddocks, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (PHASE3)
- Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (PHASE1)
- Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck (PHASE1)
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (PHASE2)
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer (PHASE1)
- GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer (PHASE2)
- Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia (PHASE2)
- P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PI3K inhibitor BKM120 CI brief — competitive landscape report
- PI3K inhibitor BKM120 updates RSS · CI watch RSS
- Kami Maddocks, MD portfolio CI